# T Cell Tech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/t-cell-tech

- Industry: Healthcare Specialists
- Headquarters: Fuzhou, China
- Website: www.tcelltech.com.cn
- Total disclosed funding: $40M
- Latest round: Series B (Jul 15, 2025)
- Investors on record: 4

## About

Based in China, T Cell Tech is a biotechnology company focused on developing innovative therapeutic solutions, particularly in the field of immunotherapy.Founded in 2017 in Fuzhou, China, T Cell Tech specializes in biotechnology with a focus on therapeutic development. The company has successfully completed one funding deal, raising USD 40.00 mn in a Series B round on July 15, 2025, led by SDIC Fund Management and supported by other investors such as Lotus Lake Capital and Industrial Guoxin Asset Management Co., Ltd. The founder's history and prior ventures are not publicly specified.T Cell Tech provides innovative therapeutic solutions primarily in the field of immunotherapy. Their offerings include a comprehensive suite of products designed to enhance treatment efficacy and patient outcomes in various medical applications. The company's solutions leverage advanced research and development techniques, targeting healthcare providers and institutions focused on cutting-edge treatments.The company generates revenue through a structured model that includes collaborations with research institutions and pharmaceutical companies. Revenue streams are bolstered by strategic partnerships aimed at advancing clinical trials and market applications of their therapeutic products. Engagements typically involve multi-year contracts that facilitate a steady influx of funds to support ongoing development efforts.Following the recent Series B funding round in July 2025, T Cell Tech plans to utilize the USD 40.00 mn raised to advance the clinical development of its core pipeline project TX-103 in both China and the United States. The company aims to expand its global presence, particularly in key markets across North America and Europe, and enhance its research and development capabilities for other pipeline projects. The funding will also support the expansion of their international team and foster business development cooperation, accelerating their strategic growth objectives.

## Funding rounds

- Series B, Jul 15, 2025, $40M — Lotus Lake Capital, SDIC Fund Management, Industrial Guoxin Asset Management Co.,Ltd., Fuzhou Mindu Talent Fund

## Investors

- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series B
- SDIC Fund Management (https://capitalatlas.ai/funds/sdic-fund-management) — Series B
- Industrial Guoxin Asset Management Co.,Ltd. — Series B
- Fuzhou Mindu Talent Fund — Series B